Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.647652/full |
id |
doaj-7828fdba5d4745f290d468c57393026f |
---|---|
record_format |
Article |
spelling |
doaj-7828fdba5d4745f290d468c57393026f2021-04-19T04:27:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-04-011210.3389/fphar.2021.647652647652Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung DiseasesSara Rolandsson Enes0Anna D. Krasnodembskaya1Karen English2Claudia C. Dos Santos3Daniel J. Weiss4Department of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, SwedenWellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Sciences, Queens University, Belfast, United KingdomCellular Immunology Laboratory, Biology Department, Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, IrelandInterdepartmental Division of Critical Care, Department of Medicine and the Keenan Center for Biomedical Research, St. Michael’s Hospital, University of Toronto, Toronto, ON, CanadaDepartment of Medicine, 226 Health Science Research Facility, Larner College of Medicine, University of Vermont, Burlington, VT, United StatesRecent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.https://www.frontiersin.org/articles/10.3389/fphar.2021.647652/fullcell therapymesenchymal stromal cells (MSCs)mscslung diseasesrespiratory diseases and disorders |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sara Rolandsson Enes Anna D. Krasnodembskaya Karen English Claudia C. Dos Santos Daniel J. Weiss |
spellingShingle |
Sara Rolandsson Enes Anna D. Krasnodembskaya Karen English Claudia C. Dos Santos Daniel J. Weiss Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases Frontiers in Pharmacology cell therapy mesenchymal stromal cells (MSCs) mscs lung diseases respiratory diseases and disorders |
author_facet |
Sara Rolandsson Enes Anna D. Krasnodembskaya Karen English Claudia C. Dos Santos Daniel J. Weiss |
author_sort |
Sara Rolandsson Enes |
title |
Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases |
title_short |
Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases |
title_full |
Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases |
title_fullStr |
Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases |
title_full_unstemmed |
Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases |
title_sort |
research progress on strategies that can enhance the therapeutic benefits of mesenchymal stromal cells in respiratory diseases with a specific focus on acute respiratory distress syndrome and other inflammatory lung diseases |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-04-01 |
description |
Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases. |
topic |
cell therapy mesenchymal stromal cells (MSCs) mscs lung diseases respiratory diseases and disorders |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.647652/full |
work_keys_str_mv |
AT sararolandssonenes researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases AT annadkrasnodembskaya researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases AT karenenglish researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases AT claudiacdossantos researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases AT danieljweiss researchprogressonstrategiesthatcanenhancethetherapeuticbenefitsofmesenchymalstromalcellsinrespiratorydiseaseswithaspecificfocusonacuterespiratorydistresssyndromeandotherinflammatorylungdiseases |
_version_ |
1721521547719475200 |